 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Prometheus Biosciences, Inc. (NASDAQ:RXDX  Get Rating) have earned a consensus rating of Hold from the eleven research firms that are covering the stock, Marketbeat Ratings reports. Seven research analysts have rated the stock with a hold recommendation and four have ...

Prometheus Biosciences, Inc. (NASDAQ:RXDX) Receives $153.36 Consensus Price Target from Brokerages

Prometheus Biosciences, Inc. (NASDAQ:RXDX Get Rating) has been given an average recommendation of Hold by the eleven analysts that are currently covering the company, Marketbeat Ratings reports. Seven analysts have rated the stock with a hold recommendation and four have given a buy recommendation ...

Brokerages Set Prometheus Biosciences, Inc. (NASDAQ:RXDX) Target Price at $153.36

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the Prometheus Biosciences, Inc. (Prometheus) (NASDAQ: RXDX) acquisition. Prometheus is now a wholly-owned subsidiary of Merck and the common stock of Prometheus will no longer be listed or...

Merck Completes Acquisition of Prometheus Biosciences, Inc.

Artia Global Partners LP bought a new stake in Prometheus Biosciences, Inc. (NASDAQ:RXDX  Get Rating) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities  Exchange Commission. The fund bought 22,321 shares of the biopharmaceutical ...

Artia Global Partners LP Acquires Shares of 22,321 Prometheus Biosciences, Inc. (NASDAQ:RXDX)

Artia Global Partners LP bought a new stake in Prometheus Biosciences, Inc. (NASDAQ:RXDX Get Rating) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 22,321 shares of the biopharmaceutical companys stock...

Avidity Partners Management LP purchased a new position in shares of Prometheus Biosciences, Inc. (NASDAQ:RXDX  Get Rating) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 204,000 shares of the ...

Avidity Partners Management LP Invests $22.44 Million in Prometheus Biosciences, Inc. (NASDAQ:RXDX)

Point72 Asset Management L.P. boosted its holdings in Prometheus Biosciences, Inc. (NASDAQ:RXDX  Get Rating) by 113.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,266,083 shares of the biopharmaceutical ...

Point72 Asset Management L.P. Boosts Stock Position in Prometheus Biosciences, Inc. (NASDAQ:RXDX)

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Prometheus Biosciences Inc (RXDX) was identified as having a larger market cap than the smaller end of the S&P 500, for example Bath & Body Works Inc (BBWI), according to The Online Investor. Click ...

Prometheus Biosciences Moves Up In Market Cap Rank, Passing Bath &amp; Body Works

Moran Wealth Management LLC acquired a new stake in Prometheus Biosciences, Inc. (NASDAQ:RXDX  Get Rating) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 5,292 shares of the biopharmaceutical company&#...

Moran Wealth Management LLC Purchases New Holdings in Prometheus Biosciences, Inc. (NASDAQ:RXDX)

Gyon Technologies Capital Management LP bought a new position in shares of Prometheus Biosciences, Inc. (NASDAQ:RXDX  Get Rating) in the fourth quarter, according to its most recent filing with the Securities  Exchange Commission. The institutional investor bought 3,285 shares of the ...

Gyon Technologies Capital Management LP Invests $361,000 in Prometheus Biosciences, Inc. (NASDAQ:RXDX)

Precision IBD is a Biotechnology company and operator of a drug development precision medicine company intended to develop therapeutics for inflammatory bowel diseases.

Market Cap	$9.56B
Volume (M)	1.86M
52-Wk High	$199.98
52-Wk Low	$25.65

Period	Estimated	Reported	Surprise	Result
Q2'23	$-0.92	--	--	N/A
Q1'23	$-0.91	$-0.86	5.55%	BEAT
Q4'22	$-0.90	$-0.90	0.11%	BEAT
Q3'22	$-0.88	$-0.90	-2.30%	MISSED
Q2'22	$-0.88	$-0.86	2.38%	BEAT

RXDX Prometheus Biosciences Inc

About

Feed

News

Earnings

Fundamentals